Clinical Effect of Rosuvastatin in Treatment of Ischemic Cerebrovascular Disease
Objective To analyze clinical effect of rosuvastatin combined with antiplatelet aggregation drugs in treatment of ischemic cerebrovascular disease.Methods The paper chose 450 patients with ischemic cerebrovascular disease from January 2019 to December 2019,and divided them into observation group(225 cases,treated with rosuvastatin combined with antiplatelet drugs)and control group(225 cases,antiplatelet drugs)with random number table method.Clinical Effect,blood lipid levels,neurological impairment(NIHSS),life quality,hemorheology,biochemical indicators,and inflammatory factors were compared.Results Clinical effect of observation group was significantly higher than control group(P＜0.05).Blood lipid levels in observation group were significantly lower than control group(P＜0.05).NIHSS scores of observation group were significantly lower than control group(P＜0.05).Life quality of observation group was significantly higher than control group(P＜0.05).Before treatment,there was little difference in plasma viscosity and hematocrit levels between two groups(P＞0.05).After treatment,plasma viscosity and hematocrit levels of observation group were significantly lower than control group(P＜0.05).UA levels in observation group were significantly lower than control group(P＜0.05).The hs CRP levels in observation group were significantly lower than control group(P＜0.05).Conclusion Rosuvastatin can achieve significant curative effect,reduce blood lipid levels,improve NIHSS scores,enhance life quality,improve hemorheological indicators,lower biochemical indicators,and reduce effect of inflammatory factors of patients effectively,with extremely important effect in improving prognosis of patients,which is worthy of widespread promotion.
NETL
NSTL
万方数据
